Carvedilol is a beta1-, beta2-, and alpha1-adrenergic blocker that is approved for the treatment of hypertension. A new once-daily, controlled-release (CR) formulation of carvedilol has been shown to be effective in a double-blind, randomized, multicenter, placebo-controlled, parallel-group study. In this article, we summarize the primary results of, and present additional analyses from, that trial. A total of 338 patients with essential hypertension (sitting diastolic blood pressure [DBP] >/=90 and 0.6 for each carvedilol CR dose. Heart rate and pulse pressure were each significantly reduced compared with placebo for each carvedilol CR dose. We conclude that carvedilol CR is a very effective antihypertensive agent with clear dose-related peak blood pressure reduction and continuous 24-hour control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2006.07.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil.
Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status.
View Article and Find Full Text PDFPrimary Diffuse Leptomeningeal Melanomatosis Leading to Raised Intracranial Pressure in a Pediatric Patient.
Clin Case Rep
February 2025
Department of Pediatrics, Division of Pediatric Neurology Children's Medical Center, Pediatrics Center of Excellent, Tehran University of Medical Sciences Tehran Iran.
A critical clinical consideration, in addition to other common risk factors predisposing individuals to idiopathic intracranial hypertension (IIH), involves the potential co-occurrence of increased intracranial pressure and elevated cerebrospinal fluid protein levels in the presence of underlying malignancies. Primary diffuse leptomeningeal melanomatosis, an exceptionally rare condition with few reported cases in the pediatric population, illustrates this scenario. Timely decision-making based on clinical suspicion to perform a biopsy and involving a skilled pathologist for accurate reporting are essential steps toward achieving a definitive diagnosis.
View Article and Find Full Text PDFShifting Paradigms in the Management of Pulmonary Hypertension.
Eur Cardiol
December 2024
Department of Respiratory Medicine, King George's Medical University Lucknow, Uttar Pradesh, India.
Pulmonary arterial hypertension (PAH) is a long-term condition characterised by increased resistance to blood flow in the pulmonary circulation. The disease has a progressive course and is associated with a poor prognosis. Without treatment, PAH is associated with mortality in <3 years.
View Article and Find Full Text PDFAssociation between different insulin resistance indices and all-cause mortality in patients with diabetic kidney disease: a prospective cohort study.
Front Endocrinol (Lausanne)
January 2025
Department of Urology, Harbin Medical University Cancer Hospital, Harbin, China.
Aim: Previous research has shown a strong association between insulin resistance (IR) and both the onset and advancement of diabetic kidney disease (DKD). This research focuses on examining the relationship between IR and all-cause mortality in individuals with DKD.
Methods: This study utilized data obtained from the National Health and Nutrition Examination Survey (NHANES), spanning the years 2001 to 2018.
Infective endocarditis following transcatheter mitral valve-in-valve replacement: a clinical case report.
BMC Cardiovasc Disord
January 2025
Department of Medical Ultrasonics, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Background: Transcatheter valve-in-valve replacement (TMViVR) is an alternative option for patients with bioprosthetic valve failure (BVF) who are at high surgical risk. Although infective endocarditis (IE) after transcatheter mitral valve-in-valve replacement is unusual, it is associated with significantly high mortality.
Case Presentation: An 81-year-old male patient was admitted with intermittent thoracic tightness, chest pain persisting for 3 years, and shortness of breath with nausea for 1 week.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!